<DOC>
	<DOCNO>NCT00478244</DOCNO>
	<brief_summary>RATIONALE : In animal model , stem cell show home skin repair biochemical structural abnormality associate recessive dystrophic epidermolysis bullosa ( RDEB ) ( collagen 7 deficiency ) . PURPOSE : To determine safety effectiveness stem cell infusion treatment RDEB .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate incidence detectable donor-derived collagen type VII day 100 patient epidermolysis bullosa donor . Secondary - Determine incidence transplant-related mortality day 180 - Determine incidence blood chimerism day 21 , 100 , 180 , 365 , 730 - Determine incidence neutrophil recovery day 42 platelet recovery day 180 - Determine incidence acute graft-versus-host disease ( GVHD ) grade II-IV grade III-IV day 100 - Determine incidence chronic GVHD 1 year - Determine probability survival 1 2 year - Determine incidence donor derive cell skin - Determine resistance blister formation OUTLINE : This open-label , pilot study . - Conditioning regimen : Busulfan intravenously ( IV ) 2 hour every 6 hour day -9 -4 , fludarabine phosphate IV 1 hour day -5 -3 , high-dose cyclophosphamide IV 1 hour day -5 -2 . - Stem cell transplantation day 0 . After completion study treatment , patient follow periodically least 5 year . PROJECTED ACCRUAL : 30 patient</detailed_description>
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Inclusion criterion : Diagnosis epidermolysis bullosa ( EB ) Documented collagen type VII deficiency : Antigenic mapping ( LH7.2 antibody ) Ultrastructure analysis anchor fibril DNA mutation analysis Performance status : &gt; 50 % Lansky ; &gt; 50 % Karnofsky Adequate organ function Renal : glomerular filtration rate &gt; 60ml/min/1.73m2 patient age â‰¤ 10 year Hepatic : bilirubin , aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) , Alkaline phosphatase ( ALP ) &lt; 5 x upper limit normal 4.2.3 Pulmonary : oxygen saturation &gt; 92 % 4.2.4 Cardiac : leave ventricular ejection fraction &gt; 45 % . Healthy relate hematopoietic stem cell donor available meeting 1 follow criterion : HLAA , B , DRB1identical sibling bone marrow and/or umbilical cord blood donor ( first priority ) HLAA , B , DRB1matched partially match related donor ( second priority ) Donor may carrier must unaffected EB 8/8 HLA A , B , C , DRB1 allele level match unrelated marrow donor ( third priority ) 7/8 HLAA , B , C , DRB1 allele level match unrelated marrow donor 4/6 HLAA , B ( antigen level ) , DRB1 ( allele level ) match unrelated cord blood donor ( fourth priority ) Exclusion criterion : Active infection time transplantation ( include active infection Aspergillus mold within 30 day ) Squamous cell carcinoma skin History human immunodeficiency virus ( HIV ) infection Prior transplantation donor skin</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>epidermolysis bullosa</keyword>
	<keyword>dystrophic epidermolysis bullosa</keyword>
</DOC>